All News

Found 9,882 articles

• Sanyou's "STAL Platform" is a significant advancement in the field of drug discovery.

  11/18/2023

  Sanyou's "STAL Innovative Biologics Drug Discovery Platform" is a significant advancement in the field of drug discovery.

• Singleron Biotechnologies announces two co-authored abstracts at the American Society of Hematology conference

  11/17/2023

  Singleron Biotechnologies has announced two co-authored abstracts for the upcoming 65th American Society of Hematology Annual Meeting & Exposition in San Diego.

• Gene Splicing Reduces Effectiveness of CD20-Targeting Monoclonal Antibodies Designed to Treat Variety of Blood Cancers and Disorders

  11/17/2023

  Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated.

• Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes

  11/17/2023

  Sana Biotechnology, Inc. and Uppsala University Hospital in Sweden today announced the Swedish Medical Products Agency has authorized Uppsala University’s Clinical Trial Application (CTA) to initiate an investigator-sponsored, first-in-human study of UP421, an allogeneic, primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, in patients with type 1 diabetes.

• Cellectis’ Shareholders Meeting to be Held on December 22, 2023

  11/17/2023

  Cellectis announced that it will hold a general meeting on December 22, 2023 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

• AffyImmune Therapeutics Awarded Best Oncology R&D Advance Scrip Award 2023

  11/17/2023

  AffyImmune Therapeutics, Inc. was awarded the first-ever Best Oncology R&D Advance at the 2023 Scrip Awards.

• CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update

  11/17/2023

  CytoMed Therapeutics Limited today announced its first half of 2023 financial results and provided clinical and corporate updates.  

• March Biosciences Awarded $13.4 Million by CPRIT to Advance Its CD5 CAR-T Therapy for T-cell Lymphoma in Phase 2 Trials

  11/17/2023

  March Biosciences (March Bio) today announced that it has received a notice of award for a major competitive grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to help support continued clinical development of its innovative chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of relapsed and refractory CD5 positive T-cell cancers.

• Gradalis Awarded $9.9 Million Grant From the Cancer Prevention and Research Institute of Texas

  11/16/2023

  Gradalis, Inc. announced that it has been awarded a $9.9 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas.

• Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit

  11/16/2023

  Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL) today announced that the Company will present at the inaugural Cell Therapy for Autoimmune Disease Summit taking place in Philadelphia and online Nov. 28-30, 2023.

• Kite and Arcellx Announce Expansion in Strategic Partnership

  11/15/2023

  Kite, a Gilead Company, and Arcellx, Inc., announced that the companies have expanded their existing collaboration, which was originally announced in December 2022.

• Arcellx and Kite Announce Expansion in Strategic Partnership

  11/15/2023

  Arcellx, Inc. and Kite, a Gilead Company, announced that the companies have expanded their existing collaboration, which was originally announced in December 2022.

• Kyverna Therapeutics Announces Publication in The Lancet Neurology of Case Report of Patient with Refractory Myasthenia Gravis Treated with Investigational KYV-101

  11/15/2023

  Kyverna Therapeutics, Inc. (Kyverna) today announced the publication in The Lancet Neurology of a Letter to the Editor by a group of German investigators describing the first case of treatment using KYV-101 in a 33 year-old patient with severe, treatment-refractory, anti-acetylcholine receptor auto-antibody positive, generalized myasthenia gravis (MG), who was treated on a named patient basis outside of a clinical trial setting.

• Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

  11/15/2023

  Cellectis anounced that, following the consultation of its works council, it has now signed a binding Subsequent Investment Agreement with AstraZeneca regarding the contemplated additional equity investment of $140M by AstraZeneca, which was previously announced on November 1, 2023.

• The Mark Foundation for Cancer Research Accelerates Commitment to Stimulate Innovation With 16 New ASPIRE Awards Totaling Over $5 Million

  11/15/2023

  The Mark Foundation for Cancer Research announced 16 outstanding projects in its latest class of ASPIRE awards, granting more than $5 million for research that aims to answer key feasibility and proof-of-concept questions in an accelerated time frame, and scaling for impact based upon initial success.

• Hemogenyx Pharmaceuticals PLC Announces Lentivirus Re-manufacturing Completed

  11/15/2023

  Hemogenyx Pharmaceuticals plc is pleased to announce the successful completion of the re-manufacturing of an improved lentivirus devoid of splice variants.

• 2seventy bio Reports Third Quarter 2023 Financial Results and Recent Operational Progress

  11/14/2023

  2seventy bio, Inc., a leading immuno-oncology cell therapy company, reported financial results and recent highlights for the third quarter ended September 30, 2023.

• CASI Pharmaceuticals Announces Third Quarter 2023 Business and Financial Updates

  11/14/2023

  CASI Pharmaceuticals, Inc. reported business and financial results for the third quarter ended September 30, 2023.

• TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results

  11/14/2023

  TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announces today that the Company has successfully completed its Safety Cohort and received positive review from the Data Safety Monitoring Board (DSMB).

• Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies

  11/14/2023

  Vittoria Biotherapeutics announced it has secured over $15 million in a private financing round.